Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €17.75 EUR
Change Today +0.39 / 2.25%
Volume 73.6K
NANO On Other Exchanges
EN Paris
As of 11:38 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

nanobiotix (NANO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - €25.00
52 Week Low
12/16/14 - €14.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOBIOTIX (NANO)

Related News

No related news articles were found.

nanobiotix (NANO) Related Businessweek News

No Related Businessweek News Found

nanobiotix (NANO) Details

Nanobiotix S.A., an oncology focused nanomedicine company, engages in the development of tools for the treatment of cancer in France and internationally. The company develops NanoXray, a pipeline of patented products that include NBTXR3 nanoparticles, which are designed for direct injection into the tumor; NBTX-IV nanoparticles designed for intravenous injection to reach the tumor and the surrounding tissue; and NBTX-TOPO nanoparticles that are formulated as a gel to be applied during surgery after removal of the tumor in various types of breast cancer, brain tumors, and retroperitoneal soft tissue sarcomas. It also develops nanoMag magnetic particles for the treatment and diagnostic of cancer; and nanoPDT laser activated nanoparticles for the treatment of cancer. The company has a business and development collaboration with Malaysian Biotech Corp. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

49 Employees
Last Reported Date: 05/1/15
Founded in 2003

nanobiotix (NANO) Top Compensated Officers

Co-Founder, President of The Executive Board ...
Total Annual Compensation: €268.8K
Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €192.0K
Chief Medical Officer, Medical Director and M...
Total Annual Compensation: €217.0K
Head of Business Development and Member of Ex...
Total Annual Compensation: €185.6K
Compensation as of Fiscal Year 2014.

nanobiotix (NANO) Key Developments

Nanobiotix SA Presents at French Life Science Days conference, Jun-17-2015

Nanobiotix SA Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3

Nanobiotix announced positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. Intermediate results show the feasibility of the injection of NBTXR3 and a good safety profile of the product for this indication. Good safety results allowing the enlargement of the targeted population to patients treated in combination with radiotherapy plus chemotherapy. One step further for use and transferability of NBTXR3 therapeutic approach in different types of tumors. This trial is an open-label non-randomized, dose escalation study. The primary objectives are the evaluation of NBTXR3 safety and tolerability. The secondary objectives of this trial include: assessment of the tumor Response Rate and complete Response Rate by MRI; evaluation of local and general Progression Free Survival of NBTXR3 and the assessment of the feasibility of local administration.

Nanobiotix SA, Annual General Meeting, Jun 25, 2015

Nanobiotix SA, Annual General Meeting, Jun 25, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:FP €17.75 EUR +0.39

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.8x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 69.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOBIOTIX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at